• Cannabidiol Attenuates Orofacial Pain via Endocannabinoid Mo

  2026-05-09

  This study provides new insight into how cannabidiol (CBD) alleviates both the sensory and affective components of orofacial inflammatory pain. By demonstrating modulation of peripheral and central endocannabinoid pathways, particularly through FAAH inhibition and anandamide elevation, the research underscores the potential for targeting these mechanisms in comprehensive pain management.

• 6-Thioguanine Suppresses EV71 by Targeting BIRC3-Mediated Au

  2026-05-08

  The referenced study demonstrates that 6-thioguanine (6-TG), an established anticancer agent, inhibits enterovirus 71 (EV71) replication in vitro by downregulating BIRC3 and disrupting autophagy. These findings reveal a novel antiviral mechanism and suggest 6-TG's potential for repurposing in EV71-associated hand, foot, and mouth disease (HFMD).

• Cyclosporin A: Optimizing Immunosuppression Workflows in Res

  2026-05-08

  Cyclosporin A, supplied by APExBIO, is indispensable for dissecting T-cell signaling, mitochondrial integrity, and immunosuppressive mechanisms. This article delivers actionable workflow enhancements, troubleshooting strategies, and advanced applications grounded in recent mechanistic insights.

• Bazedoxifene Inhibits IL-6/GP130: Implications for Cancer Th

  2026-05-07

  Shi et al. (2024) demonstrate that bazedoxifene, beyond its established use as a selective estrogen receptor modulator, acts as a targeted inhibitor of the IL-6/GP130 signaling pathway, a key driver in cancer proliferation and survival. This review synthesizes mechanistic insights and preclinical evidence for repositioning bazedoxifene as an anti-cancer agent, highlighting its potential to enhance therapeutic strategies against cytokine-driven tumors.

• Clozapine in Translational Schizophrenia Research: Pathways

  2026-05-07

  This article delivers a thought-leadership perspective on Clozapine as an atypical antipsychotic medication, offering mechanistic depth and strategic guidance for translational neuroscience. It integrates the latest molecular psychiatry findings—such as ERK1/2 signaling activation and EGF receptor-mediated effects—into experimental design and protocol optimization. By contextualizing Clozapine's unique pharmacology within the competitive landscape of neuromodulation and noninvasive brain stimulation, we chart actionable directions for researchers navigating preclinical and translational schizophrenia models. Protocol parameters and evidence are provided with precise attributions, and APExBIO's Clozapine is positioned as a foundational tool for advanced research.

• RNA Pol II Inhibition Drives Apoptosis via PDAR, Not mRNA De

  2026-05-06

  Harper et al. (2025) reveal that cell death from RNA polymerase II inhibition is not a passive consequence of mRNA or protein depletion. Instead, apoptosis is triggered by the loss of the hypophosphorylated RNA Pol IIA form, defining a new regulated PDAR pathway with broad implications for apoptosis research and drug mechanism understanding.

• Bradykinin B2 Receptors Inhibit Ileal Peristalsis via Pressu

  2026-05-06

  This study provides direct experimental evidence that bradykinin B2 receptor activation inhibits the peristaltic reflex in the guinea pig isolated ileum by increasing the pressure threshold required for peristalsis. These findings clarify the specific role of B2 receptors in gastrointestinal motility and highlight important implications for ACE inhibitor research and experimental design in hypertension and bradykinin pathway studies.

• Rotenone in Immunometabolic and Neurodegenerative Research

  2026-05-05

  Explore how Rotenone, a mitochondrial Complex I inhibitor, bridges mitochondrial dysfunction and immunometabolic research. This article uniquely integrates neurodegenerative disease modeling with new insights into macrophage metabolic reprogramming.

• Tacrine Hydrochloride Hydrate in Neurodegenerative Disease M

  2026-05-05

  Tacrine hydrochloride hydrate (Tetrahydroaminacrine) is a benchmark AChE inhibitor for probing cholinergic signaling and neuroprotection in Alzheimer's disease research. This guide delivers workflow optimizations, experimental troubleshooting, and translational insights built around APExBIO’s high-purity formulation for reproducible, high-impact results.

• Hesperadin: Precision Aurora B Kinase Inhibitor Workflows

  2026-05-04

  Hesperadin from APExBIO empowers researchers to dissect mitotic progression, spindle assembly checkpoint disruption, and chromosome segregation defects with precision. This guide delivers actionable protocols, troubleshooting tips, and cutting-edge insights that translate bench research into robust, reproducible results.

• COX-2 Pathway Dynamics in Bothropic Venom-Induced Muscle Inj

  2026-05-04

  This study elucidates the nuanced role of the cyclooxygenase-2 (COX-2) pathway in modulating tissue ischemia and revascularization after skeletal muscle injury by Bothrops asper venom. Using temporally controlled inhibition with Lumiracoxib, the research reveals a dual-phase effect of COX-2 on vascular repair, offering insights for targeted intervention in muscle regeneration models.

• RITA (NSC 652287): Reliable MDM2-p53 Inhibition for Cancer B

  2026-05-03

  Explore how RITA (NSC 652287), available as SKU A4202, addresses critical challenges in cell-based cancer biology workflows. This scenario-driven guide integrates evidence-based analysis, real-world protocol optimization, and candid product selection advice to support reproducible, data-rich research.

• Optimizing Cancer Assays with YM-155 Hydrochloride: Survivin

  2026-05-02

  YM-155 hydrochloride empowers apoptosis inhibitor research with nanomolar precision, enabling robust modeling of tumor regression in xenograft and in vitro cancer systems. This article delivers workflow-centric strategies, experimental parameters, and troubleshooting tactics for maximizing the scientific value of this selective survivin inhibitor.

• AG-120 (Ivosidenib): Translational Leverage in IDH1-Mutant A

  2026-05-01

  This article explores the mechanistic underpinnings, translational potential, and evolving research strategies surrounding AG-120 (Ivosidenib) as a mutant IDH1 inhibitor in acute myeloid leukemia (AML). Integrating recent discoveries on metabolic rewiring via the CD44 axis, we offer strategic guidance for researchers seeking to optimize 2-hydroxyglutarate reduction, myeloid differentiation induction, and resistance management. By bridging evidence-based protocol guidance with a forward-looking perspective, this piece advances the translational conversation beyond standard product profiles.

• Moesin as a Biomarker of Endothelial Injury in Sepsis: Key I

  2026-05-01

  This study establishes moesin (MSN) as a potential biomarker for endothelial injury in sepsis, demonstrating its association with disease severity and vascular dysfunction. Experimental evidence links MSN expression to inflammatory signaling pathways and endothelial permeability, offering new directions for early diagnosis and translational research.

15476 records 1/1032 page Next 12345 下5页 Last page